Abstract
There is an increasing interest in the potential role of low molecular weight heparins (LMWHs) in the management of cancer patients. These antithrombotic agents have generated particular excitement because they have been proved useful in both the prevention and treatment of venous thromboembolism (VTE) in patients with malignancy. Recent reports are, at the same time, highlighting a potential role of LMWHs on patient survival due to their presumed antineoplastic action. This review will discuss the most recent reports and patents on these topics.
Keywords: Low molecular weight heparins (LMWH), antithrombotic agents, antitumor therapy, venous thromboembolism (VTE)
Recent Patents on Anti-Cancer Drug Discovery
Title: Low Molecular Weight Heparins as Antineoplastic Agents
Volume: 3 Issue: 3
Author(s): Sergio Siragusa
Affiliation:
Keywords: Low molecular weight heparins (LMWH), antithrombotic agents, antitumor therapy, venous thromboembolism (VTE)
Abstract: There is an increasing interest in the potential role of low molecular weight heparins (LMWHs) in the management of cancer patients. These antithrombotic agents have generated particular excitement because they have been proved useful in both the prevention and treatment of venous thromboembolism (VTE) in patients with malignancy. Recent reports are, at the same time, highlighting a potential role of LMWHs on patient survival due to their presumed antineoplastic action. This review will discuss the most recent reports and patents on these topics.
Export Options
About this article
Cite this article as:
Siragusa Sergio, Low Molecular Weight Heparins as Antineoplastic Agents, Recent Patents on Anti-Cancer Drug Discovery 2008; 3 (3) . https://dx.doi.org/10.2174/157489208786242287
DOI https://dx.doi.org/10.2174/157489208786242287 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Urokinase Receptor in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Preface [Hot Topic: Marine Natural Products (Guest Editor: Vassilios Roussis)]
Current Medicinal Chemistry Recent Insights on the Medicinal Chemistry of Metal-Based Compounds: Hints for the Successful Drug Design
Current Medicinal Chemistry Targeted Drug Delivery to Cancer Stem Cells through Nanotechnological Approaches
Current Stem Cell Research & Therapy Exosomal MicroRNAs in Tumoral U87 MG Versus Normal Astrocyte Cells
MicroRNA Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology Treatment Approaches in Elderly Patients with Head and Neck Cancer
Anti-Cancer Agents in Medicinal Chemistry EGFR Mutation Testing in Non-Small Cell Lung Cancer
Current Respiratory Medicine Reviews Oncorine, the World First Oncolytic Virus Medicine and its Update in China
Current Cancer Drug Targets Pain Biomarkers in Cancer: An Overview
Current Pharmaceutical Design Antioxidant Food Supplements and Obesity-Related Inflammation
Current Medicinal Chemistry Antioxidant Potential of Solvent Partitioned Extraction from Aqueous Extract of Gracilaria Tenuistipitata
Current Organic Chemistry Ellipticine, its Derivatives: Re-evaluation of Clinical Suitability with the Aid of Drug Delivery Systems
Current Cancer Drug Targets Ganglioside GM3 and Its Role in Cancer
Current Medicinal Chemistry Nanotechnology Platforms; An Innovative Approach to Brain Tumor Therapy
Medicinal Chemistry Drug Eluting Stents and Beyond
Current Pharmaceutical Design Crystal Structures and Cytotoxicity of Ortho-Xylene Linked Bis-benzimidazolium Salts
Medicinal Chemistry Recent Advances in Drug Design of Epidermal Growth Factor Receptor Inhibitors
Current Medicinal Chemistry Genome-Wide Integrated Analyses of Androgen Receptor Signaling in Prostate Cancer Based on High-Throughput Technology
Current Drug Targets Updates for Chest Tumors
Current Cancer Therapy Reviews